Use of RPL as a prognostic parameter

Oct 13, 2025 by wbrum.org 34 views

Relationship between Lymphocyte Platelet Ratios and Coronary Artery Lesions in Patients with Acute Myocardial Infarction at the Adam Malik Medan Hajj Center General Hospital

Introduction

Coronary heart disease (CHD) remains a major cause of morbidity and mortality worldwide. The complex pathophysiology of this condition involves inflammatory reactions, which play a crucial role in the development of CHD. One of the parameters that has garnered attention in recent studies is the lymphocyte platelet ratio (RPL), a prognostic indicator that combines two variables, platelets and lymphocytes, into a single value to predict the atherosclerotic process. This study aims to explore the relationship between RPL and the severity of coronary arterial lesions in acute myocardial infarction patients undergoing coronary angiography.

Background

Coronary heart disease is a multifactorial condition that involves the interplay of various risk factors, including hypertension, diabetes, high cholesterol, and smoking. The inflammatory process plays a significant role in the development of CHD, leading to the formation of atherosclerotic plaques in the coronary arteries. The lymphocyte platelet ratio (RPL) has emerged as a potential prognostic indicator for CHD, as it combines the effects of platelets and lymphocytes on the atherosclerotic process.

Research Methods

This study is a prospective study conducted from August to December 2019, involving 60 patients diagnosed with acute coronary syndrome and treated at the Emergency Department of the Adam Malik Medan Hajj Center General Hospital. Various variables were evaluated, including a history of comorbidity, laboratory examination, and coronary angiography results. Before the angiographic action was carried out, the RPL value was calculated and divided into two groups: one group with a RPL of less than 116, and one more group with RPL of more than 116. The syntax score generated from coronary angiography was also divided into two groups: patients with low scores (less than 23) and patients with moderate to high scores (23 or more).

Research Result

Of the total 60 patients studied, it was found that 25 patients (41%) had a syntax score of 23 or more, while 35 patients (58%) had a score of less than 23. This study showed a significant difference between the two groups. The analysis using the Chi-Square method indicates a significant statistical relationship between the lymphocyte platelet ratio and the syntax score, with the Odds Ratio (OR) value of 8.7 and the P value of less than 0.001.

Discussion

The results of this study suggest that there is a significant relationship between lymphocyte platelet ratios and coronary artery lesions severity in patients who experience acute coronary syndrome. This finding is consistent with previous studies that have demonstrated the prognostic value of RPL in predicting the risk of cardiovascular events. The RPL can be used as a prognostic parameter that is useful for assessing the patient's condition and the risk of further complications.

Conclusion

In conclusion, this study provides important insights for medical personnel in handling patients with coronary heart disease. The findings of this study suggest that the lymphocyte platelet ratio can be used as a prognostic parameter to assess the severity of coronary artery lesions in patients with acute myocardial infarction. This study opens the way for further research that can explore more about the mechanism of inflammation and aggregation that contribute to this disease.

Recommendations

Based on the findings of this study, the following recommendations are made:

Use of RPL as a prognostic parameter: The RPL can be used as a prognostic parameter to assess the severity of coronary artery lesions in patients with acute myocardial infarction.
Further research: Further research is needed to explore the mechanism of inflammation and aggregation that contribute to coronary heart disease.
Development of new therapeutic strategies: New therapeutic strategies can be developed based on the findings of this study, which can help to improve the management of patients with coronary heart disease.

Limitations

This study has several limitations, including:

Small sample size: The sample size of this study is relatively small, which may limit the generalizability of the findings.
Selection bias: The study population may be subject to selection bias, which may affect the validity of the findings.
Limited follow-up: The follow-up period of this study is relatively short, which may limit the ability to assess the long-term outcomes of patients with coronary heart disease.

Future Directions

Future studies should aim to:

Explore the mechanism of inflammation and aggregation: Further research is needed to explore the mechanism of inflammation and aggregation that contribute to coronary heart disease.
Develop new therapeutic strategies: New therapeutic strategies can be developed based on the findings of this study, which can help to improve the management of patients with coronary heart disease.
Validate the prognostic value of RPL: The prognostic value of RPL should be validated in larger and more diverse populations to confirm its utility as a prognostic parameter.
Frequently Asked Questions (FAQs) about the Relationship between Lymphocyte Platelet Ratios and Coronary Artery Lesions in Patients with Acute Myocardial Infarction

Q: What is the lymphocyte platelet ratio (RPL)?

A: The lymphocyte platelet ratio (RPL) is a prognostic indicator that combines two variables, platelets and lymphocytes, into a single value to predict the atherosclerotic process.

Q: What is the significance of the RPL in coronary heart disease?

A: The RPL has emerged as a potential prognostic indicator for coronary heart disease, as it combines the effects of platelets and lymphocytes on the atherosclerotic process.

Q: What is the relationship between RPL and coronary artery lesions in patients with acute myocardial infarction?

A: This study found a significant relationship between RPL and coronary artery lesions severity in patients with acute myocardial infarction, suggesting that the RPL can be used as a prognostic parameter to assess the severity of coronary artery lesions.

Q: What are the implications of this study for medical personnel?

A: The findings of this study suggest that the RPL can be used as a prognostic parameter to assess the severity of coronary artery lesions in patients with acute myocardial infarction, which can help medical personnel to make informed decisions about patient care.

Q: What are the limitations of this study?

A: This study has several limitations, including a small sample size, selection bias, and limited follow-up.

Q: What are the future directions for research in this area?

A: Future studies should aim to explore the mechanism of inflammation and aggregation that contribute to coronary heart disease, develop new therapeutic strategies, and validate the prognostic value of RPL in larger and more diverse populations.

Q: Can the RPL be used as a diagnostic tool for coronary heart disease?

A: While the RPL has emerged as a potential prognostic indicator for coronary heart disease, it is not yet clear whether it can be used as a diagnostic tool for the disease.

Q: What are the potential benefits of using the RPL as a prognostic parameter?

A: The potential benefits of using the RPL as a prognostic parameter include improved patient outcomes, reduced morbidity and mortality, and more effective management of patients with coronary heart disease.

Q: What are the potential risks of using the RPL as a prognostic parameter?

A: The potential risks of using the RPL as a prognostic parameter include misinterpretation of results, over-reliance on a single prognostic indicator, and potential biases in patient selection.

Q: How can the RPL be used in clinical practice?

A: The RPL can be used in clinical practice as a prognostic parameter to assess the severity of coronary artery lesions in patients with acute myocardial infarction, and to inform decisions about patient care.

Q: What are the next steps for research in this area?

A: The next steps for research in this area include further exploration of the mechanism of inflammation and aggregation that contribute to coronary heart disease, development of new therapeutic strategies, and validation of the prognostic value of RPL in larger and more diverse populations.